Initiate a Phase 3 study of ALXN2040 as an add-on therapy
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 30 Jul 2020
- Due
- 31 Dec 2020
- Delivered
- December 2020
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Alexion plans to initiate a Phase 3 study of ALXN2040 as an add-on therapy for PNH patients with EVH by the end of 2020.”
What we found
Evidence strength A What the grades mean
A February 2021 8-K says the Phase 3 study was initiated in December 2020, before the year-end deadline; a later 10-K says first-patient dosing occurred in Q1 2021.
-
A Alexion Pharmaceuticals 8-K filed 2021-02-04
“In December 2020, Alexion initiated a Phase 3 study of ALXN2040 as an add-on therapy for PNH patients with EVH and dosing is underway.” ✓ confirmed on the page
-
A Alexion Pharmaceuticals 10-K filed 2021-02-08
“and a Phase III trial for PNH-EVH was initiated, with dosing of the first patient in the first quarter of 2021.” ✓ confirmed on the page
Checked 21 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 3 study of ALXN2040
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Alexion Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2020-C899866-019398 · Corrections policy